Welcome to our dedicated page for Galecto news (Ticker: GLTO), a resource for investors and traders seeking the latest updates and insights on Galecto stock.
Galecto, Inc. (GLTO) is a clinical-stage biotechnology company at the forefront of developing innovative treatments for fibrosis and cancer. Founded in Lund, Sweden, and now incorporated in the U.S., Galecto focuses on small-molecule inhibitors targeting galectin-3 and lysyl oxidase-like 2 (LOXL2), proteins integral to the pathology of fibrosis and various cancers.
The company's lead product candidates include GB0139, GB1211, and GB2064. GB0139, initially developed for idiopathic pulmonary fibrosis (IPF), has shown promising preclinical results but recently failed to meet its primary endpoint in the Phase 2b GALACTIC-1 trial. Consequently, Galecto will discontinue its development and redirect resources.
GB1211, a selective oral galectin-3 inhibitor, targets severe liver diseases like non-alcoholic steatohepatitis (NASH) and liver cirrhosis. Encouraging results from the GULLIVER-2 trial underscored significant biomarker improvements and a favorable safety profile, setting the stage for the upcoming Phase 2a GULLIVER-3 trial in early 2024.
GB2064, an oral LOXL2 inhibitor, is in Phase 2a trials for myelofibrosis. Preliminary data indicate significant reductions in bone marrow fibrosis, validating the compound’s potential as a disease-modifying therapy.
Galecto's strategic partnerships and collaborations with top-tier scientists and biotech executives position it well for future growth. The company is also exploring GB1211's potential in oncology, specifically in combination with checkpoint inhibitors to overcome treatment resistance in cancers like non-small cell lung cancer (NSCLC) and melanoma.
With approximately $49 million in cash and investments, Galecto aims to extend its cash runway into 2025, focusing on advancing its promising pipeline of orally administered compounds.
For the latest updates and detailed information about Galecto, visit their website at www.galecto.com.
BOSTON, Feb. 1, 2023 (GLOBE NEWSWIRE) -- Galecto, a clinical-stage biotechnology company focused on fibrosis and cancer treatments, will present at the SVB Securities Global Biopharma Conference from February 14-16, 2023. The presentation is scheduled for February 14th at 8:00 AM EST. A live webcast will be available on Galecto's Investor website, along with a replay following the event.
Currently, Galecto is developing small molecule inhibitors targeting galectin-3 and LOXL2, with four ongoing Phase 2 trials including treatments for idiopathic pulmonary fibrosis and non-small cell lung cancer.
Galecto, Inc. (NASDAQ: GLTO) announced an intermediate assessment of its Phase 2 MYLOX-1 trial for GB2064, an oral LOXL2 inhibitor targeting myelofibrosis. The study showed that 4 out of 5 evaluable patients experienced a significant reduction in collagen fibrosis, indicating potential disease-modifying effects. The results will be presented at the ASH Annual Meeting on December 10, 2022. The trial focuses on patients refractory to JAK inhibitors, with GB2064 administered at 1000mg twice daily. The preliminary findings suggest that GB2064 effectively engages its target and penetrates fibrotic bone marrow.
Galecto, Inc. (NASDAQ: GLTO), a biotechnology company, reported its Q3 2022 results, highlighting successful outcomes from clinical trials. The Phase 1b/2a GULLIVER-2 trial showed GB1211 reduced liver impairment signs in patients with cirrhosis. The Phase 2a MYLOX-1 trial indicated GB2064 effectively reduced collagen fibrosis in myelofibrosis patients. Although the net loss was $13.7 million, cash reserves of $75.9 million are expected to sustain operations into mid-2024. Upcoming milestones include top-line results from the GALACTIC-1 trial in mid-2023.
Galecto, Inc. (NASDAQ: GLTO) reported promising topline results from its Phase 1b/2a GULLIVER-2 trial of GB1211, focusing on severe liver diseases. The trial showed statistically significant reductions in liver enzymes ALT, AST, and GGT after 12 weeks, with GB1211 demonstrating encouraging results in various liver function markers. The data indicates potential liver protection and improvement in patients with decompensated cirrhosis. Further development for GB1211 is anticipated, given its favorable safety profile and encouraging efficacy.
BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto (NASDAQ: GLTO), a clinical-stage biotechnology company, will present at the Jefferies London Healthcare Conference on November 16, 2022, at 7:25 am GMT. The presentation will focus on its advancements in galectin biology aimed at treating fibrosis and cancer. A live webcast can be accessed here and a replay will be available on Galecto's Investor website following the event. The company is currently developing therapies for idiopathic pulmonary fibrosis, myelofibrosis, liver cirrhosis, and non-small cell lung cancer.
Galecto (NASDAQ: GLTO) presented data from its completed Phase 1b/2a GULLIVER-2 trial at The Liver Meeting 2022. The trial evaluated GB1211, a galectin-3 inhibitor, for severe liver diseases. Topline data showed GB1211 was well-tolerated, with encouraging clinical efficacy, including reduced liver enzyme levels and improved liver fat measurements. The results support further development of GB1211 in severe cirrhosis, addressing a critical unmet need for treatment options. A webinar is scheduled for November 8, 2022, to discuss the findings in detail.
Galecto, Inc. (NASDAQ: GLTO) announced a collaboration for a Phase 2 trial at Providence Cancer Institute to evaluate the safety and efficacy of GB1211, a galectin-3 inhibitor, combined with pembrolizumab (Keytruda). This investigator-initiated trial aims to counteract checkpoint inhibitor resistance in melanoma and head and neck squamous cell carcinoma (HNSCC) patients. The randomized trial will start in 2023, with top-line results expected by 2025. GB1211 has shown promise in previous studies, demonstrating a well-tolerated profile and potential anti-cancer effects.
Galecto, Inc. (NASDAQ: GLTO) announced a live conference call and webcast on November 8, 2022, at 8:00 am ET to discuss topline data from the GULLIVER-2 trial for liver cirrhosis. The trial assesses the safety and efficacy of GB1211, an oral galectin-3 inhibitor, in up to 54 participants with decompensated cirrhosis. The trial includes both randomized and open-label study parts, focusing on pharmacokinetics and therapeutic potential. Interested individuals can join the webcast through a provided link, and a replay will be accessible on the investor relations website.
Galecto, Inc. (NASDAQ: GLTO) announced positive results from its Phase 2a MYLOX-1 trial of GB2064 for myelofibrosis on September 29, 2022. Out of five evaluable patients, four showed a ≥ 1-grade reduction in collagen fibrosis after six months of GB2064 treatment, indicating potential disease modification. Patients also exhibited stable hematological parameters without the need for transfusions. The drug demonstrated a generally acceptable tolerability profile, though some patients discontinued due to adverse events. Company leadership highlighted these results as a proof of principle for GB2064's anti-fibrotic effects.
Galecto, Inc. (NASDAQ: GLTO), a biotechnology firm, announced participation in H.C. Wainwright’s 24th Annual Global Investment Conference from September 12-14, 2022. Management will engage in virtual 1x1 meetings with investors, and a webcast of the presentation will be available for replay on Galecto’s website. The company focuses on developing inhibitors for fibrosis and cancer, with four ongoing Phase 2 clinical trials targeting conditions like idiopathic pulmonary fibrosis and non-small cell lung cancer.
FAQ
What is the current stock price of Galecto (GLTO)?
What is the market cap of Galecto (GLTO)?
What does Galecto, Inc. specialize in?
What are Galecto's key product candidates?
Why is Galecto discontinuing GB0139?
What are the next steps for GB1211?
What recent achievements has Galecto made?
How is GB1211 expected to help cancer patients?
What is Galecto's financial condition?
Where is Galecto headquartered?
Who leads Galecto, Inc.?
Where can I find more information about Galecto?
